Catalog No.S1747 Synonyms: BAY E 9736

For research use only.

Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure.

Nimodipine Chemical Structure

CAS No. 66085-59-4

Selleck's Nimodipine has been cited by 3 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Calcium Channel Inhibitors

Other Calcium Channel Products

Biological Activity

Description Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure.
Calcium channel [1]
In vitro

Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine (100 nM) significantly reduces the AHP in aging CA1 neurons. Nimodipine increases excitability in an age- and concentration-dependent manner by decreasing spike frequency accommodation (increasing the number of action potentials during prolonged depolarizing current injection). Nimodipine decreases accommodation only at higher concentrations in young CA1 neurons. [1] Nimodipine decreases the plateau phase of the calcium AP at concentrations as low as 100 nM in aging neurons and 10 mM in young rat neurons. [2]

In vivo Nimodipine results in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it becomes positive. [3] Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, appears to completely block the establishment of conditioning of cocaine's effects, but only partially blocks sensitization to cocaine. [4] Nimodipine (5-20 mg/kg, SC) inhibits in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 418.44


CAS No. 66085-59-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04998370 Recruiting -- Subarachnoid Hemorrhage Aneurysmal|Vasospasm|Delayed Cerebral Ischemia|Delayed Ischemic Neurological Deficit University of Zurich August 18 2021 --
NCT04649398 Recruiting Drug: Nimodipine Subarachnoid Hemorrhage Aneurysmal|Delayed Cerebral Ischemia|Vasospasm Cerebral Medical University of Vienna|University of Vienna|Austrian Science Fund (FWF) November 25 2020 --
NCT02991157 Completed Drug: Nimodipine Subarachnoid Hemorrhage Aneurysmal National Institute of Mental Health and Neuro Sciences India December 2016 --
NCT01835665 Completed Drug: Nimodipine Progranulin Mutation Carriers University of California San Francisco|The Bluefield Project to Cure Frontotemporal Dementia March 2013 Phase 1
NCT01551368 Terminated Drug: Nimodipine|Drug: Placebo Infertility Mount Sinai Hospital Canada December 2012 Phase 2
NCT01220622 Unknown status Drug: Nimodipine|Drug: Placebo Stroke|Mild Cognitive Impairment Ministry of Science and Technology of the People´s Republic of China October 2010 Phase 4

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Nimodipine | Nimodipine supplier | purchase Nimodipine | Nimodipine cost | Nimodipine manufacturer | order Nimodipine | Nimodipine distributor